Identification of sedative-hypnotic compounds shared by five medicinal Polyporales mushrooms using UPLC-Q-TOF-MS/MS-based untargeted metabolomics.

Medicinal Polyporales mushrooms Sedative-hypnotic compounds Untargeted metabolomics

Journal

Phytomedicine : international journal of phytotherapy and phytopharmacology
ISSN: 1618-095X
Titre abrégé: Phytomedicine
Pays: Germany
ID NLM: 9438794

Informations de publication

Date de publication:
12 Jan 2024
Historique:
received: 03 09 2023
revised: 02 01 2024
accepted: 11 01 2024
medline: 1 4 2024
pubmed: 1 4 2024
entrez: 31 3 2024
Statut: aheadofprint

Résumé

Five Polyporales mushrooms, namely Amauroderma rugosum, Ganoderma lucidum, G. resinaceum, G. sinense and Trametes versicolor, are commonly used in China for managing insomnia. However, their active components for this application are not fully understood, restricting their universal recognition. In this study, we aimed to identify sedative-hypnotic compounds shared by these five Polyporales mushrooms. A UPLC-Q-TOF-MS/MS-based untargeted metabolomics, including OPLS-DA (orthogonal projection of potential structure discriminant analysis) and OPLS (orthogonal projections to latent structures) analysis together with mouse assays, were used to identify the main sedative-hypnotic compounds shared by the five Polyporales mushrooms. A pentobarbital sodium-induced sleeping model was used to investigate the sedative-hypnotic effects of the five mushrooms and their sedative-hypnotic compounds. Ninety-two shared compounds in the five mushrooms were identified. Mouse assays showed that these mushrooms exerted sedative-hypnotic effects, with different potencies. Six triterpenes [four ganoderic acids (B, C1, F and H) and two ganoderenic acids (A and D)] were found to be the main sedative-hypnotic compounds shared by the five mushrooms. We for the first time found that these six triterpenes contribute to the sedative-hypnotic ability of the five mushrooms. Our novel findings provide pharmacological and chemical justifications for the use of the five medicinal mushrooms in managing insomnia.

Sections du résumé

BACKGROUND BACKGROUND
Five Polyporales mushrooms, namely Amauroderma rugosum, Ganoderma lucidum, G. resinaceum, G. sinense and Trametes versicolor, are commonly used in China for managing insomnia. However, their active components for this application are not fully understood, restricting their universal recognition.
PURPOSE OBJECTIVE
In this study, we aimed to identify sedative-hypnotic compounds shared by these five Polyporales mushrooms.
STUDY DESIGN AND METHODS METHODS
A UPLC-Q-TOF-MS/MS-based untargeted metabolomics, including OPLS-DA (orthogonal projection of potential structure discriminant analysis) and OPLS (orthogonal projections to latent structures) analysis together with mouse assays, were used to identify the main sedative-hypnotic compounds shared by the five Polyporales mushrooms. A pentobarbital sodium-induced sleeping model was used to investigate the sedative-hypnotic effects of the five mushrooms and their sedative-hypnotic compounds.
RESULTS RESULTS
Ninety-two shared compounds in the five mushrooms were identified. Mouse assays showed that these mushrooms exerted sedative-hypnotic effects, with different potencies. Six triterpenes [four ganoderic acids (B, C1, F and H) and two ganoderenic acids (A and D)] were found to be the main sedative-hypnotic compounds shared by the five mushrooms.
CONCLUSION CONCLUSIONS
We for the first time found that these six triterpenes contribute to the sedative-hypnotic ability of the five mushrooms. Our novel findings provide pharmacological and chemical justifications for the use of the five medicinal mushrooms in managing insomnia.

Identifiants

pubmed: 38555773
pii: S0944-7113(24)00020-5
doi: 10.1016/j.phymed.2024.155355
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

155355

Informations de copyright

Copyright © 2024. Published by Elsevier GmbH.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Wei Chen (W)

Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China.

Jun-Wen Yu (JW)

Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China.

Yu-Yi Deng (YY)

Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China.

Lut Yi Wong (LY)

Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China.

Chen Wang (C)

Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China.

Yu-Ling Liang (YL)

Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China.

Yuk-Tung Leung (YT)

Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China.

Jia-Yi Tian (JY)

Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China.

Ying Wu (Y)

Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China.

Kelvin Sze-Yin Leung (KS)

Department of Chemistry, Hong Kong Baptist University, Hong Kong 999077, China.

Jinhui Hu (J)

School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, China.

Wen-Hua Chen (WH)

School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, China.

Xiaobing Dou (X)

School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310000, China.

Xiu-Qiong Fu (XQ)

Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China.

Ying-Jie Chen (YJ)

Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China; Drug Clinical Trial Institution, the First Affiliated Hospital, School of Medicine, Xiamen University, Xiamen 361000, China. Electronic address: 19482256@life.hkbu.edu.hk.

Zhi-Ling Yu (ZL)

Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong 999077, China. Electronic address: zlyu@hkbu.edu.hk.

Classifications MeSH